GlassScriptPhysician profile
Thomas D Richardson
NPI 1699773069
$4,529.77
in general payments reported to CMS, 2019-2025
30 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $177 · 2021: $511 · 2022: $379 · 2023: $415 · 2024: $152 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,274 · Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,273.65 |
| Food and Beverage | $717.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,273.65 | 2025 | Nanoknife |
| Isoray, INC | $951.91 | 2019-2023 | Brachytherapy Source |
| 180 Medical, INC. | $425.13 | 2019-2024 | Gentlecath, Cure Catheter, Gentlecath Glide |
| Janssen Biotech, INC. | $280.39 | 2019-2022 | |
| Teleflex LLC | $224.55 | 2021-2024 | Urolift |
| Dendreon Pharmaceuticals LLC | $222.91 | 2019-2024 | Provenge |
| Abbvie INC. | $125.67 | 2022-2024 | |
| Progenics Pharmaceuticals, INC. | $124.73 | 2023-2025 | Pylarify |
| Astellas Pharma US INC | $114.59 | 2020-2024 | Xtandi |
| Axonics, INC. | $103.41 | 2021-2023 | Bulkamid, Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $75.90 | 2019-2025 | |
| Coloplast Corp | $69.69 | 2020-2022 | |
| Neotract INC. | $62.75 | 2019 | |
| Pfizer INC. | $60.61 | 2019-2025 | |
| Boston Scientific Corporation | $57.10 | 2019-2025 | Axonics, Advance Xp |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih INC. | $50.95 | 2019 | |
| Urogen Pharma, INC. | $42.59 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $36.70 | 2025 | Aptra |
| Blue Earth Diagnostics | $35.00 | 2019 | |
| Merck Sharp & Dohme LLC | $30.73 | 2023 | Keytruda, Welireg, Lynparza |
| Endo Pharmaceuticals INC. | $29.48 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $19.67 | 2023 | Trelstar |
| Laborie Medical Technologies Corp. | $17.35 | 2021 | |
| Medtronic USA, INC. | $16.59 | 2019 | |
| Cook Medical LLC | $16.19 | 2022 | |
| Telix Pharmaceuticals | $13.96 | 2023 | Illuccix |
| Vertex Pharmaceuticals Incorporated | $13.52 | 2025 | |
| Myovant Sciences INC. | $13.38 | 2021 | |
| Palette Life Sciences, INC. | $12.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.